INmune Bio reports press release available
INMB•Commercial manufacturing milestone for CORDStrom platform
- INmune Bio disclosed completion of a commercial manufacturing milestone for its CORDStrom platform, supporting planned global registration filings.
- First commercial-ready umbilical cord tissue was processed at the UK Cell and Gene Therapy Catapult under an agreement with Anthony Nolan.
- Manufacturing is positioned to support a planned Phase 3 confirmation trial for Ebstrocel in RDEB, targeting US, EU, UK submissions.
- Update cited alignment with the MHRA draft rare disease therapies regulatory framework; consultation link: https://www.gov.uk/government/consultations/draft-rare-disease-therapies-regulatory-framework.
